Literature DB >> 12669474

Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.

Roger H Kennett1.   

Abstract

Wilex AG, in collaboration with the Ludwig Institute for Cancer Research, is developing WX-G250, a kappa light chain chimeric antibody derived from the variable region of the mouse monoclonal antibody G250, for the potential treatment of biliary cancer and renal cell carcinoma (RCC). The antibody is currently undergoing phase II clinical trials for RCC and preclinical development for biliary cancer.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12669474

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  1 in total

1.  CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.

Authors:  P J Adam; J A Terrett; G Steers; L Stockwin; J A Loader; G C Fletcher; L-S Lu; B I Leach; S Mason; A C Stamps; R S Boyd; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2006-08-07       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.